Insight Molecular Diagnostics (IMDX) Non-Current Debt (2017 - 2021)

Insight Molecular Diagnostics has disclosed Non-Current Debt across 5 years of filings, most recently posting $178000.0 for Q3 2021.

• Non-Current Debt for Q3 2021 came in at $178000.0, down 91.38% year-over-year; the trailing twelve-month figure through Sep 2021 was $178000.0 (down 91.38% YoY), and the FY2020 annual result was $1.5 million, down 20.84% from the prior year.
• Non-Current Debt came in at $178000.0 for Q3 2021 at Insight Molecular Diagnostics, down from $541000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $2.6 million in Q2 2020 to a low of $159000.0 in Q1 2019.
• The 5-year median for Non-Current Debt is $1.1 million (2017), against an average of $1.1 million.
• Across the five-year window, Non-Current Debt soared 884.28% in 2020 and sank 91.38% in 2021, its largest moves.
• Insight Molecular Diagnostics' Non-Current Debt stood at $1.1 million in 2017, then plunged by 67.57% to $347000.0 in 2018, then soared by 448.99% to $1.9 million in 2019, then fell by 20.84% to $1.5 million in 2020, then plunged by 88.2% to $178000.0 in 2021.
• The last three Non-Current Debt figures came in at $178000.0 (Q3 2021), $541000.0 (Q2 2021), and $951000.0 (Q1 2021), per Business Quant data.